All Clinical Resources

25 - 36 of 81 results

Close to the Heart: The Increasing Prevalence of Type 2 Diabetes and Associated Comorbidities

Industry Podcast Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.; Not for CME/CE Credit

Listen as Dr. Eden Miller and Dr. James O’Keefe discuss how diabetes can affect cardiovascular health. These key experts will also review key cardiovascular outcomes trials and their impact on treatment guidance for patients with type 2 diabetes.


Close to the Heart: Assessing Cardiovascular Risk Factors in Our Patients with Type 2 Diabetes

Industry Podcast Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.; Not for CME/CE Credit

Dr. Eden Miller and Dr. James O’Keefe discuss the impact of cardiovascular risk factors on patients with type 2 diabetes, and how leading medical associations prioritize cardiovascular risk in patient care.


How to Recognize the Potential Signs of IPF and Understand When Patients Should be Referred to an ILD Center

Industry Podcast Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.; Not for CME/CE Credit

During this podcast, expert pulmonologists who specialize in the field of interstitial lung disease (ILD) focus on recognizing and referring patients with signs of potential idiopathic pulmonary fibrosis For more interstitial lung disease (ILD) educational content, please visit www.InsightsinILD.com


Improving the Management of Patients with IPF Through Disease, Symptom, and Support-Centered Management

Industry Podcast Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.; Not for CME/CE Credit

During this podcast, expert pulmonologists who specialize in the field of interstitial lung disease (ILD) focus on how to manage the care of patients with IPF through disease, symptom and support-centered strategies with an emphasis on how all of these components and various healthcare specialties work together to help the patient in their journey. For more interstitial lung disease (ILD) educational content, please visit www.InsightsinILD.com


Managing ILD Patients During the COVID Pandemic

Industry Podcast Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.; Not for CME/CE Credit

During this podcast, an expert pulmonary nurse provides an overview of interstitial lung diseases and discusses high-risk patients and their concerns during the era of COVID-19 For more interstitial lung disease (ILD) educational content, please visit www.InsightsinILD.com


Identifying High-Risk Patients With ASCVD and Reducing the Burden of Elevated LDL-C

Industry Podcast Sponsored by Novartis Pharmaceuticals Corporation, US Medical Affairs; Not for CME/CE Credit

This podcast discusses the identification and management of patients with atherosclerotic cardiovascular disease (ASCVD) and highlights opportunities to reduce the overall burden of elevated low-density lipoprotein cholesterol (LDL-C).


When Is LDL-C Low Enough?

Industry Podcast Sponsored by Novartis Pharmaceuticals Corporation, US Medical Affairs; Not for CME/CE Credit

This podcast discusses the management of low-density lipoprotein cholesterol (LDL-C) and addresses the concept of when LDL-C levels are “low enough” to reduce the risk for atherosclerotic cardiovascular disease.


Shared Decision-Making in Lipid Management

Industry Podcast Sponsored by Novartis Pharmaceuticals Corporation, US Medical Affairs; Not for CME/CE Credit

This podcast discusses when patients who are at high risk of cardiovascular disease should be comanaged by primary care providers and lipidologists.


Senior patient sitting on hospital chair, smiling looking at camera

Addressing Low Detection of Chronic Kidney Disease in At-Risk Patients

Industry Webcast Sponsored by Labcorp; Not for CME/CE Credit


lipoprotein cell close up

Lipoprotein(a) Learning Module

An Adaptive Learning Experience Sponsored by Novartis Pharmaceuticals Corporation; Not for CME/CE CreditThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

Lipoprotein(a) is a genetically determined LDL-C like particle that is uniquely proatherogenic, prothrombotic, and proinflammatory. While emerging therapies are on the horizon, there are no current FDA approved medicinal treatment options for Lp(a). Understanding the prevalence and need to test for Lp(a) will help your patients mitigate potential cardiovascular risks via lifestyle modification and informing clinical practice. This interactive module will cover: • The differences between LDL-C and Lp(a) • Testing and incidence of Lp(a), as well as associated diseases • Cardiovascular risk and risk-enhancing factors that can lead to cardiovascular events • Lifestyle management and risk factor mitigation


Overview title image tile

Revolutionizing the Management of Your Patients with CKD at Risk of Progression With and Without T2D

Industry Webcast Sponsored by AstraZeneca Pharmaceuticals, LP; Not for CME/CE Credit


Addressing Elevated Risk For Thrombotic CV Events in Patients Across the CAD Spectrum

Industry Webcast Sponsored by AstraZeneca Pharmaceuticals, LP; Not for CME/CE Credit